Search Within

Steven M Sugarman

Formats
  1. Meeting Abstract (23)
  2. Journal Article (16)
Groups
  1. Breast Medicine Service (39)
  2. Department of Medicine (39)
  3. Solid Tumor Oncology Division (39)
  4. Survivorship Research (39)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (32)
  6. Epidemiology and Biostatistics (27)

More Groups

People
  1. Clifford Hudis (37)
  2. Larry Norton (29)
  3. Chau Dang (23)
  4. Gabriella D'Andrea-Carlino (20)
  5. Diana Lake (17)
  6. Sujata Patil (17)

More People

Years
  1. 2021 (1)
  2. 2017 (3)
  3. 2016 (3)
  4. 2015 (3)
  5. 2014 (2)
  6. 2011 (4)

More Years

Publications
  1. Breast Cancer Research and Treatment (11)
  2. Journal of Clinical Oncology (10)
  3. Cancer Research (7)
  4. Clinical Breast Cancer (4)
  5. Clinical Cancer Research (3)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. Springer (11)
  2. American Association for Cancer Research (10)
  3. American Society of Clinical Oncology (10)
  4. Elsevier Inc. (5)
  5. Oxford University Press (2)
  6. Pergamon-Elsevier Science Ltd (1)

Results (39)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Consolidative use of radiotherapy to block (CURB) oligoprogression: Interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast
    Meeting Abstract

    Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Shepherd, A. F.; Eng, J.; Gelblum, D.; Xu, A. J.; Namakydoust, A.; Iqbal, A.; more...
    International Journal of Radiation Oncology, Biology, Physics (2021)

    Fulltext@MSK | Save
  • Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance)
    Journal Article

    Bluethmann, S. M.; Alfano, C. M.; Clapp, J. D.; Luta, G.; Small, B. J.; Hurria, A.; Cohen, H. J.; Sugarman, S.; Muss, H. B.; Isaacs, C.; more...
    Breast Cancer Research and Treatment (2017)

    Fulltext@MSK | Save
  • Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance)
    Journal Article

    Mandelblatt, J. S.; Cai, L.; Luta, G.; Kimmick, G.; Clapp, J.; Isaacs, C.; Pitcher, B.; Barry, W.; Winer, E.; Sugarman, S.; more...
    Breast Cancer Research and Treatment (2017)

    Fulltext@MSK | Save
  • Pathologic complete response with neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single center experience
    Journal Article

    Singh, J. C.; Mamtani, A.; Barrio, A.; Morrow, M.; Sugarman, S.; Jones, L. W.; Yu, A. F.; Argolo, D.; Smyth, L. M.; Modi, S.; more...
    The Oncologist (2017)

    Fulltext@MSK | Save
  • Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: Overall survival and updated progression-free survival results from a phase II study
    Journal Article

    Smyth, L. M.; Iyengar, N. M.; Chen, M. F.; Popper, S. M.; Patil, S.; Wasserheit-Lieblich, C.; Argolo, D. F.; Singh, J. C.; Chandarlapaty, S.; Sugarman, S. M.; more...
    Breast Cancer Research and Treatment (2016)

    Fulltext@MSK | Save
  • Pathologic complete response rate with doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single institution experience
    Meeting Abstract

    Singh, J. C.; Sugarman, S.; Jones, L.; Boafo, C.; Patil, S.; Schweber, S.; Yu, A.; Argolo, D.; Modi, S.; Iyengar, N.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • A pilot study of dose-dense paclitaxel with trastuzumab and lapatinib for node-negative HER2-overexpressed breast cancer
    Journal Article

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S. M.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G. M.; Drullinsky, P. R.; Gajria, D.; Goldfarb, S. B.; Comen, E. A.; more...
    Clinical Breast Cancer (2016)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result
    Meeting Abstract

    Smyth, L. M.; Iyengar, N. M.; Chandarlapaty, S.; Sugarman, S.; Comen, E. A.; Drullinsky, P.; Sklarin, N. T.; Traina, T. A.; Troso-Sandoval, T. A.; Patil, S.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save